Reviewing Seaport Therapeutics (SPTX) & Its Competitors

Seaport Therapeutics (NASDAQ:SPTX) is one of 906 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Seaport Therapeutics to related businesses based on the strength of its risk, earnings, dividends, institutional ownership, analyst recommendations, profitability and valuation.

Valuation and Earnings

This table compares Seaport Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Seaport Therapeutics	N/A	-$74.88 million	-1.93
Seaport Therapeutics Competitors	$3.48 billion	$3.12 billion	548.24

Seaport Therapeutics’ rivals have higher revenue and earnings than Seaport Therapeutics. Seaport Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings for Seaport Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	2	3	6	0	2.36
Seaport Therapeutics Competitors	7719	13663	25550	994	2.41

Seaport Therapeutics currently has a consensus target price of $37.33, indicating a potential upside of 59.20%. As a group, “Pharmaceuticals” companies have a potential upside of 30.56%. Given Seaport Therapeutics’ higher probable upside, equities research analysts plainly believe Seaport Therapeutics is more favorable than its rivals.

Profitability

This table compares Seaport Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Seaport Therapeutics Competitors	-2,303.77%	-221.69%	-17.78%

Institutional & Insider Ownership

32.8% of shares of all “Pharmaceuticals” companies are held by institutional investors. 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Seaport Therapeutics rivals beat Seaport Therapeutics on 7 of the 12 factors compared.

Seaport Therapeutics Company Profile

Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.